142 related articles for article (PubMed ID: 36815815)
1. Osteoporosis Drug Increases Hypocalcemia Risk in Dialysis Patients.
Aschenbrenner DS
Am J Nurs; 2023 Mar; 123(3):20. PubMed ID: 36815815
[TBL] [Abstract][Full Text] [Related]
2. Safety of denosumab in dialysis patients on calcium and vitamin D supplements.
Ullah A; Abdulnabi K; Khalil A; Alexander J; Pai P; Mishra V
Saudi J Kidney Dis Transpl; 2017; 28(1):158-161. PubMed ID: 28098118
[No Abstract] [Full Text] [Related]
3. In brief: Severe hypocalcemia with denosumab (Prolia) in chronic kidney disease.
Med Lett Drugs Ther; 2024 Mar; 66(1697):40. PubMed ID: 38412278
[No Abstract] [Full Text] [Related]
4. High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis.
Ishikawa K; Nagai T; Tsuchiya K; Oshita Y; Kuroda T; Ito H; Tani S; Dodo Y; Toyone T; Inagaki K
Clin Interv Aging; 2018; 13():1929-1934. PubMed ID: 30349211
[TBL] [Abstract][Full Text] [Related]
5. Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients.
Bird ST; Smith ER; Gelperin K; Jung TH; Thompson A; Kambhampati R; Lyu H; Zhao H; Zhao Y; Zhu Y; Easley O; Niak A; Wernecke M; Chillarige Y; Zemskova M; Kelman JA; Graham DJ
JAMA; 2024 Feb; 331(6):491-499. PubMed ID: 38241060
[TBL] [Abstract][Full Text] [Related]
6. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.
Thongprayoon C; Acharya P; Acharya C; Chenbhanich J; Bathini T; Boonpheng B; Sharma K; Wijarnpreecha K; Ungprasert P; Gonzalez Suarez ML; Cheungpasitporn W
Osteoporos Int; 2018 Aug; 29(8):1737-1745. PubMed ID: 29713798
[TBL] [Abstract][Full Text] [Related]
7. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.
Dave V; Chiang CY; Booth J; Mount PF
Am J Nephrol; 2015; 41(2):129-37. PubMed ID: 25790847
[TBL] [Abstract][Full Text] [Related]
8. Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.
Saito S; Sugo Y; Tsuburai T; Kurasawa K; Nakamura T; Yoshikata H; Miyagi E; Sakakibara H
J Obstet Gynaecol Res; 2019 Apr; 45(4):908-914. PubMed ID: 30618176
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of denosumab in osteoporotic hemodialysed patients.
Festuccia F; Jafari MT; Moioli A; Fofi C; Barberi S; Amendola S; Sciacchitano S; Punzo G; Menè P
J Nephrol; 2017 Apr; 30(2):271-279. PubMed ID: 27394428
[TBL] [Abstract][Full Text] [Related]
10. Rapid progression of vascular and soft tissue calcification while being managed for severe and persistent hypocalcemia induced by denosumab treatment in a patient with multiple myeloma and chronic kidney disease.
Ueki K; Yamada S; Tsuchimoto A; Tokumoto M; Kumano T; Kitazono T; Tsuruya K
Intern Med; 2015; 54(20):2637-42. PubMed ID: 26466702
[TBL] [Abstract][Full Text] [Related]
11. Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis.
Yasuda Y; Iwama S; Arima H
Endocr J; 2019 Mar; 66(3):271-275. PubMed ID: 30713246
[TBL] [Abstract][Full Text] [Related]
12. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.
Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112
[TBL] [Abstract][Full Text] [Related]
13. Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.
Saito Y; Takekuma Y; Komatsu Y; Sugawara M
Biol Pharm Bull; 2021; 44(12):1819-1823. PubMed ID: 34853264
[TBL] [Abstract][Full Text] [Related]
14. Life-threatening hypocalcaemia associated with denosumab in advanced chronic kidney disease.
Killen JP; Yong K; Luxton G; Endre Z
Intern Med J; 2016 Jun; 46(6):746-7. PubMed ID: 27257154
[No Abstract] [Full Text] [Related]
15. Severe hypocalcemia after denosumab administration in a patient with chronic kidney disease: a case report.
Kouroglou E; Tsiama V; Dionysopoulou S; Gavriiloglou G; Bora M; Belis K; Proikaki S; Savvidis C; Giannou P; Petras D
J Musculoskelet Neuronal Interact; 2023 Jun; 23(2):285-289. PubMed ID: 37259667
[TBL] [Abstract][Full Text] [Related]
16. Reducing the risk of denosumab-induced hypocalcemia in patients with advanced chronic kidney disease: a quality improvement initiative.
Kanagalingam T; Khan T; Sultan N; Cowan A; Thain J; Hoy C; Ledger S; Clemens KK
Arch Osteoporos; 2023 Nov; 18(1):138. PubMed ID: 37985504
[TBL] [Abstract][Full Text] [Related]
17. Denosumab-associated hypocalcemia: Does gender play a role?
Diker-Cohen T; Amitai O; Shochat T; Shimon I; Tsvetov G
Maturitas; 2020 Dec; 142():17-23. PubMed ID: 33158483
[TBL] [Abstract][Full Text] [Related]
18. Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study.
Hiramatsu R; Ubara Y; Sawa N; Sakai A
Nephrol Dial Transplant; 2021 Sep; 36(10):1900-1907. PubMed ID: 33544866
[TBL] [Abstract][Full Text] [Related]
19. Treatment of osteoporosis with denosumab in patients with decreased kidney function.
Svendsen OL
Arch Osteoporos; 2023 Jul; 18(1):104. PubMed ID: 37495795
[TBL] [Abstract][Full Text] [Related]
20. Denosumab-induced severe hypocalcaemia in a patient with vitamin D deficiency.
Daga N; Joseph F
BMJ Case Rep; 2020 Aug; 13(8):. PubMed ID: 32847872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
